Previous 10 | Next 10 |
AMRYT REPORTS RECORD Q3 2020 RESULTS 19% YoY revenue growth in the quarter to $49.3M Raising full year revenue guidance to $180M - $182M Both metreleptin and lomitapide driving revenue performance and growth Strong cash generation with cash of $75.4M at Sep...
AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA LATE-BREAKING ORAL PRESENTATION AT THE 29 TH EADV (VIRTUAL) CONGRESS ON OCTOBER 31 Virtual Analyst & Investor Event | Tuesday November 3 at 0830 EST / 1330 GMT Regi...
Amryt (AMYT) has selected Swixx BioPharma AG of Baar, Switzerland as exclusive distributor of Lojuxta (lomitapide) from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North M...
AMRYT PHARMA PLC (“ Amryt ” or the “ Company ”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR LOJUXTA ® ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”) DUBLIN, Ireland, and Boston MA, October 1...
AMRYT PHARMA PLC (“ Amryt ” or the “ Company ”) AMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020 DUBLIN, Ireland, and Boston MA, October 14 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...
AMRYT PHARMA PLC (“ Amryt ” or the “ Company ”) AMRYT SUPPORTS GLOBAL FH AWARENESS DAY – SEPTEMBER 24, 2020 DUBLIN, Ireland, and Boston MA, September 23 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage bioph...
AMRYT PHARMA PLC (“ Amryt ” or the “ Company ”) Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights DUBLIN, Ireland, and Boston MA, September 21 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-st...
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products has issued a positive opinion backing Orphan Drug status for the use of Amryt's (NASDAQ: AMYT ) AP103 in Epidermolysis Bullosa (EB). More news on: Amryt Pharma, Healthcare stocks news, Read more ...
Amryt ( AMYT +23.6% ) has announced positive topline data from its Phase 3 EASE trial of Filsuvez (AP101 /Oleogel-S10) for dystrophic and junctional Epidermolysis Bullosa (EB). More news on: Amryt Pharma, Amryt Pharma plc, Healthcare stocks news, Stocks on the move, Read more ......
Gainers: Superconductor Technologies (NASDAQ: SCON ) +85% . More news on: Superconductor Technologies Inc., Intra-Cellular Therapies, Inc., Nuverra Environmental Solutions, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...